Prothena (PRTA) said Thursday the phase 2b study conducted by partner Roche evaluating prasinezumab for the treatment of early-stage Parkinson's disease missed its primary endpoint.
However, the study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints, the company said.
The results will therefore be used to inform future clinical development of the drug candidate as a potential disease-modifying treatment for patients with Parkinson's disease.
Meanwhile, Roche is further evaluating the data and will work with health authorities to determine the next steps.
Prothena's share price fell over 6% in recent premarket activity Thursday.
Price: 11.21, Change: -0.74, Percent Change: -6.19
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。